Thus, the targeted expression panel consisted altogether of 65 genes, which were previously identified in 2126 individuals with IBD and 34 individuals with RA as potential predictors for different anti-TNF therapy (ADA, IFX, golimumab) responses in peripheral blood of CD, UC, unclassified IBD or RA patients18,20–22. The gene discussed is ADA; the disease is inflammatory bowel disease.